diazooxonorleucine has been researched along with Cancer of Pancreas in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, S; Dudeja, V; Durden, BC; Ferrantella, A; Garrido, VT; Giri, B; Gupta, VK; Hadad, R; Kesh, K; Saluja, A; Sharma, NS | 1 |
| Brentnall, TA; Chen, R; Jung, L; Lai, LA; Pan, S; Pillarisetty, VG; Riddell, J; Sullivan, Y; Wang, L; Wong, M | 1 |
| Adams, WE; Curphey, TJ; Daniel, DS; Lilja, HS; Longnecker, DS | 1 |
3 other study(ies) available for diazooxonorleucine and Cancer of Pancreas
| Article | Year |
|---|---|
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.
Topics: Animals; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Diazooxonorleucine; Female; Hexosamines; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Xenograft Model Antitumor Assays | 2020 |
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Diazooxonorleucine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glutamine; Humans; Metabolic Networks and Pathways; Oxidation-Reduction; Pancreatic Neoplasms; Proteomics | 2017 |
Studies of DNA damage in rat pancreas and liver by 6-diazo-5-oxo-L-norleucine, ethyl diazoacetate and azaserine.
Topics: Animals; Azaserine; Azo Compounds; Carcinogens; Diazonium Compounds; Diazooxonorleucine; DNA; Liver; Pancreas; Pancreatic Neoplasms; Rats; Rats, Inbred Strains | 1981 |